Back to results
US 2008/0188521 A1Published application
Novel pharmaceutical compounds
AssigneeMerck Sharp & Dohme Corp.
InventorsErich L. Grimm, Yves Ducharme, Richard Frenette, Richard Friesen, Marc Gagnon, Helene Juteau, Sebastien Laliberte, Bruce MacKay, Yves Gareau
Life of this patent
Estimating the term…
Abstract
The instant invention provides compounds of Formula I which are leukotriene biosynthesis inhibitors. Compounds of Formula I are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
Claims27
A compound of structural Formula I
- or a pharmaceutically acceptable salt thereof wherein:
- is selected from the group consisting of
- wherein the numbers “1” and “2” indicate the points of attachment within structural Formula I;
- is selected from a single and a double bond;
- A is selected from the group consisting of:
- (a) a 5-membered heteroaryl ring containing (i) one or more carbon atoms, (ii) one heteroatom selected from oxygen and sulfur, and (iii) zero, one, two or three nitrogen atoms,
- (b) a 5-membered heteroaryl ring containing one or more carbon atoms and from one to four nitrogen atoms,
- (c) a 6-membered heteroaryl ring containing carbon atoms and one, two or three nitrogen atoms,
- (d) a bicyclic ring system selected from benzothienyl, indolyl, quinolinyl and naphthalenyl,
- (e) morpholinyl,
- (f) phenyl,
- (g) benzyl,
- (h) chloro, and
- (i) —C(O)C1-3alkyl,
- and wherein A is optionally mono- or di-substituted with a substituent independently selected at each occurrence from the group consisting of (i) fluorine, (ii) chlorine, (iii) —C1-3 alkyl optionally substituted with one to five fluorines, (iv) —C1-3 alkoxy optionally substituted with one to five fluorines, (v) C3-6 cycloalkyloxy, (vi) —C1-3alkyl-OH, (vii) —COOR8, (viii) —CN, (ix) —NR7R8, and (x) —SO2C1-3alkyl;
- W is H or methyl;
- X is selected from the group consisting of pyridinyl, -Ph, and —C(R2)(R3)(R4);
- Y is selected from —CH2— and —CH2CH2—;
- R1 is selected from the group consisting of —H, —C1-6alkyl and —C3-6cycloalkyl;
- R1a is selected from the group consisting of:
- (a) —H, (b) —Cl, (c) —CN, (d) —COOR8, (e) —CONR7R8, (f) —C(S)NR7R8, (g) —S(O)p—C1-3alkyl, (h) —NR7R9, (i) —C(═N—OH)—CH3, (j) —C(═N—OCH3)—CH3, (k) —C(═NH)—OCH3, (l) —C1-6alkyl optionally mono- or di-substituted with a substituent independently selected at each occurrence from the group consisting of —OH and —F, (m) —C1-3alkyl-O—C1-3alkyl, (n) —C1-3alkoxy optionally substituted with one to five fluorines, (o) —C1-3alkoxy, (p) —C3-6cycloalkyl, (q) phenyl optionally mono- or di-substituted with a substituent independently selected at each occurrence from the group consisting of —OH and —F, (r) pyridinyl optionally substituted with —C1-3alkyl, particularly methyl, (s) 1-pyrrolidinyl, (t) 4-morpholinyl, and (u) 1-piperazinyl optionally 4N-substituted with —C1-3 alkyl particularly methyl;
- p is an integer selected from zero, 1 and 2;
- R2 is selected from the group consisting of —H, —OH, —F, —C1-3alkyl, —OC1-3alkyl, —OC(O)—C1-13alkyl, and —OC(O)-phenyl wherein phenyl is optionally substituted with a group selected from —OH and —NO2;
- and —O-cyclic alkyl ether wherein the cyclic alkyl ether is comprised of one oxygen and 2-5 carbon atoms;
- R3 is selected from the group consisting of —H, —C1-6alkyl, —C1-6alkyl substituted with one or more of fluoro, —C1-6alkyl substituted with R6, phenyl, —C2-6alkenyl, —C3-6cycloalkyl, and —C5-7cycloalkenyl;
- R4 is selected from the group consisting of —H, —C1-6alkyl, —C1-6alkyl substituted with one or more of fluoro, —C1-6alkyl substituted with R6, phenyl, —C2-6alkenyl, —C3-6cycloalkyl, and —C5-7cycloalkenyl;
- or R3 and R4 are joined together with the carbon to which they are attached to form a ring selected from —C3-6cycloalkyl, and a 3-6 membered cyclic alkyl ether comprised of one oxygen and 2-5 carbon atoms;
- C5-7 cycloalkenyl, provided that there is no double bond at the C-1 position in the ring;
- or R2, R3 and R4 are joined together with the carbon to which they are attached to form 1-cyclopentenyl or 1-cyclohexenyl;
- R5 is independently selected at each occurrence from the group consisting of —H, —C1-6 alkyl and —C3-6cycloalkyl;
- R6 is independently selected at each occurrence from the group consisting of —COOR8, —C(O)H, —CN, —CR5R5OH, —OR5, —S—C1-6alkyl and —S—C3-6 cycloalkyl;
- R7 is selected from the group consisting of —H, —C1-6 alkyl, —C3-6 cycloalkyl and —COOR8;
- R8 is selected from the group consisting of —H, —C1-6 alkyl and —C3-6 cycloalkyl;
- and
- R9 is independently selected from the group consisting of —H, —C1-6 alkyl, and —C3-6 cycloalkyl, phenyl and benzyl.
32 more elements
20-25. (canceled)
Dependencies are inferred from the claim text.